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Abstract  
Background: Life style changes and statins are the cornerstones in management of 
dyslipidemia in HIV-infected patients. Replacement of an antiretroviral therapy 
(ART) component is a proposed therapeutic strategy to reduce cardiovascular risk. In 
dyslipidemic HIV-positive patients, we assessed the efficacy of replacing boosted 
protease inhibitor (bPI) or efavirenz (EFV) by etravirine (ETR) as an alternative to 
statin therapy. 
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Materials and methods: A prospective, open-label, multicentre, 12-week study of 
HIV-infected patients on ART including bPI or EFV, and statin treatment. Four 
weeks after statin interruption, bPI or EFV were switched to ETR (400 mg, 8 weeks) 
if serum low-density lipoprotein cholesterol (LDL-c) was ≥ 3 mmol/L. The primary 
endpoint was the proportion of patients on ETR with no indication for statin 
treatment at study completion. Serum levels of HIV-RNA, lipids, and biomarkers of 
cardiovascular disease were also measured. (ClinicalTrials.gov: NCT01543035).   
Results: The 31 included patients had a HIV1-RNA <50 copies/mL (median age, 52 
years; median CD4, 709 cell/mL; median LDL-c, 2.89 mmol/L), 68% were on EFV, 
32% on bPI. At week 4, 27 patients switched to ETR. At study completion, 15 
patients (56%) on ETR did not qualify for statin treatment. After the ETR switch, 
serum levels of the cardiovascular biomarkers sICAM and MCP1/CCL2 decreased 
by 11.2% and 18.9%, respectively, and those of CCL5/RANTES and tissue inhibitor 
of metalloproteinase-1 increased by 14.3% and 13.4%, respectively, indicating 
reduced cardiovascular risk. There were no notable treatment-related adverse events.  
Conclusions: Replacing bPI or EFV by ETR is a viable strategy to obviate primary 
prevention statin treatment. 
 
Introduction 
Dyslipidaemia is common among HIV-infected individuals and has been associated 
with the HIV infection itself and antiretroviral treatment-induced metabolic disorders 
[1-6]. Dyslipidaemia is associated with the development of cardiovascular disease in 
HIV-positive patients on anti-retroviral therapy (ART) [7-9]. Moreover, plasma 
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levels of several markers of cardiovascular disease are positively associated with 
HIV-RNA replication [10]. Therefore, HIV-positive patients are often prescribed 
lipid-lowering drugs, such as statins, for primary prevention of cardiovascular 
disease. However, the relationship between specific antiretroviral drugs, known risk 
factors, and biological markers is unclear.  
 
The replacement of antiretroviral drugs rather than adjunction of an anti-lipidaemic 
drug is a recommended strategy in the 2013 European AIDS Clinical Society 
(EACS) guidelines [11], considering the potential risk of drug-drug interactions 
between ART and statins [12] and the importance of reducing pill-burden. This 
treatment strategy might also decrease the levels of atherosclerotic inflammatory 
biomarkers. 
 
We have, together with other groups, previously highlighted the beneficial effect of 
etravirine (ETR) on lipid profile [13-14], and we aimed to investigate the efficacy 
and safety of replacing ritonavir-boosted lopinavir (LPV/r), atazanavir (ATZ/r), 
darunavir (DRV/r), or efavirenz (EFV) with etravirine (ETR) as a strategy to obviate 
statin treatment in patients with suppressed viremia (HIV RNA below 50 copies/mL) 
and no history of cardiovascular events.  
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In addition, we assessed the effects of this treatment on serum levels of biomarkers 
of endothelial activation, pro-atherosclerotic inflammatory cytokines and 
chemokines, adipocytokines, and metalloproteases and their inhibitors. 
 
Subjects and Methods 
Study design and population 
This was a 12-week prospective, open label, multicentre, phase III study carried out 
in 6 sites participating in the Swiss HIV Cohort Study (SHCS) in Switzerland 
between February 2012 and December 2013. The study was approved by the ethics 
committee of each site and conducted according to Good Clinical Practices [15] and 
applicable laws and regulations. All patients provided informed consent. 
(ClinicalTrials.gov identifier, NCT01543035).  
 
Eligible for study inclusion were HIV-infected adults (18–70 years old) with stable, 
undetectable HIV-1 RNA (less than 50 copies/mL for at least the 3 previous months) 
on combined ART with boosted ATZ, DRV, LPV, or EFV, and on statin therapy for 
primary prevention since at least 3 months, with no history of hyperlipidaemia before 
ART initiation. Non-inclusion criteria were as follows: >20% ten year cardiovascular 
risk using the Swiss Atherosclerosis Association GSLA score [16]; use of statins 
before ART initiation; diabetes; and history of drug resistance mutation (except for 
K103N).  
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At baseline, all participants interrupted their statin treatment for 4 weeks. At week 4, 
patients with serum levels of low-density lipoproteins (LDL-c) ≥ 3 mmol/L, i.e., 
those qualifying for continued statin treatment, were switched from the on-going PI 
or EFV to ETR, 400 mg (2 tablets of 200 mg) once daily for 8 weeks, while patients 
who had lower levels of LDL-c continued the on-going ART without statin 
treatment. All patients were followed up for the subsequent 8 weeks, with an optional 
visit 2 weeks after the ETR switch to assess possible side effects. We performed 
laboratory biochemical tests for lipid profile, liver function, glycaemia, HIV-1 RNA, 
and cardiovascular risk profile, as well as clinical assessment at baseline (week 0), 
switch to ETR (week 4), and end of study (week 12). 
 
Outcomes 
The primary endpoint of the study was the proportion of patients not qualifying for 
statin treatment 8 weeks after the ETR switch, i.e. at study completion (week 12). 
The need for statin treatment was determined according to the 2013 treatment 
guidelines of the EACS for patients with low-to-moderate risk of cardiovascular 
disease on the basis of the Framingham CHD Score [17] and the Swiss 
cardiovascular risk score GSLA. In a post-hoc analysis we applied the recently 
issued 2013 ACC/AHA guidelines (10-year atherosclerosis and cardiovascular risk) 
[18]. 
 
Secondary endpoints included changes in serum level of lipids and biomarkers 
relative to baseline at week 4 for all included patients; changes relative to week 4 at 
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the end of study were determined for patients who switched to ETR. We also 
recorded serum levels of HIV-RNA at baseline and study completion.  
 
Biochemical determinations 
Lipid profile determination was performed centrally (Covance laboratory, Meyrin, 
Switzerland, LAP Number 4658701, AU-ID 1190700). LDL-c was calculated with 
the Friedwald formula or measured directly if triglycerides (TG) were above 4.52 
mmol/L. All other tests were performed locally in quality controlled, SHCS (Swiss 
HIV Cohort Study, www.shcs.ch) -affiliated laboratories. All the above tests were 
performed at week 0, 4, and 12. HIV-1 RNA was measured using Roche COBAS 
TaqMan HIV-1 test version 2.0 (COBAS AmpliPrep; Roche Diagnostic, Basel, 
Switzerland) and was considered undetectable if below 50 copies/mL.  
 
Inflammatory markers were measured retrospectively, at study completion, at the 
Department of Laboratory Medicine, Cardiology Laboratory of the University 
Hospital of Geneva.  
 
We performed batch measurements using colorimetric Enzyme-Linked 
Immunosorbent Assay (ELISA) following manufacturer’s instructions for serum 
soluble intercellular adhesion molecule (sICAM)-1, soluble vascular cell adhesion 
molecule (sVCAM)-1, interleukin (IL)-6, monocyte chemoattractant protein-1 
(MCP-1)/CCL2, and tumour necrosis factor (TNF)-alpha (all from BioLegend, San 
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Diego, California, USA); for tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-
2, matrix metalloproteinase (MMP)-8, macrophage inflammatory protein (MIP)-
1beta/CCL4, regulated upon activation, normal T-cell expressed, and secreted 
(RANTES)/CCL5, E-selectin, L-selectin, C-reactive protein (CRP) and leptin (all 
from RayBiotech Inc., Norcross, GA, USA); for serum tissue inhibitors of 
metalloproteases, TIMP-1, TIMP-2, and TIMP-3 (all from Abcam, Cambridge, MA, 
USA); for serum adiponectin, MMP-8, MMP-9, and soluble (s)P-selectin (all from 
R&D Systems, Minneapolis, Minnesota, USA); and for plasma D-dimer 
(Technoclone Gmbh, Vienna, Austria). Mean intra- and inter-assay coefficients of 
variation (CV) were below 15% for all markers.  
 
The limits of detection of the markers were as follows: 0.78 ng/mL for sICAM-1, 
1.56 ng/mL for sVCAM-1, 24.69 pg/mL for TIMP-1, 1.6 pg/mL for TIMP-2, 
156 pg/m for TIMP-3, 0.312 ng/m for MMP-9, 8.23 pg/m for MMP-8, 2.74 pg/mL 
for RANTES/CCL5, 24.69 pg/mL for E-selectin, 0.99 ng/mL for sP-selectin, 
0.102 ng/mL for L-selectin, 2.469 pg/mL for CRP, 15.6 pg/mL for TNF-alpha, 
7.8 pg/mL for IL-6, 1.64 pg/mL for leptin, 3.9 ng/mL for adiponectin, 7.8 pg/mL for 
MCP-1/CCL2, 4.10 pg/mL for MIP-1beta/CCL4 and 212 ng/mL for D-dimer. 
 
Among promising cardiovascular mediators involved in atherosclerotic acceleration 
in HIV patients [10, 19], we focused on markers of endothelial activation (soluble 
adhesion molecules, such as sICAM, sVCAM, E-Selectin, sP-selectin, L-Selectin), 
pro-atherosclerotic molecules cytokines and chemokines (CRP, IL-6, TNF alpha, 
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MCP1/CCL2, MIP-1-beta/CCL4 and CCL5 RANTES), adipocytokines (leptin and 
adiponectin) and coagulation factors (d-dimer). Considering the potential vulnerable 
properties of metalloproteases on atherosclerotic plaques [20-21], we investigated 
serum levels of the collagenase MMP-8, the gelatinase MMP-9 and their tissue 
inhibitors (TIMP-1, -2 and -3).  
 
Data collected during the study visits, including laboratory values, were monitored, 
and entered into a CRF compliant electronic database (SecuTrial®). 
 
Safety assessment 
Adverse Events were graded according to the Division of AIDS (DAIDS) Table for 
Grading of Severity of Adult Adverse Events, (Version 1.0 December 2004, 
Clarification August 2009,  www.niaid.nih.gov). Reporting of Severe Adverse 
Events was to be compliant with applicable Swiss laws and regulations. 
 
All included patients were followed up for safety assessment until the week 12 visit. 
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Statistical Analysis 
Sample size estimation 
The following hypotheses were made: during the 4 weeks without statin treatment, 
up to 10% of the patients would show LDL-c value below the threshold level of 
3 mmol/L and therefore would not be eligible for the drug switch to ETR. The 
proportion of patients in need of statin treatment would decrease to 25% at study 
completion. With a power of 80% and a significance level of 5%, we estimated a 
total of 40 eligible patients would be required to show a decrease of at least 25% of 
patients in need of statin. 
 
Data Analysis 
Baseline characteristics included: age, weight, sex, menopausal status, pregnancy, 
smoking status, systolic blood pressure, myocardial infarct/stroke in first degree 
relative, diabetes, treated hypertension, cardiovascular risk level (GSLA score [16], 
Framingham Hard CHD Score [17]), HIV stage according to  the Centre for Disease 
Control (CDC) classification, on-going ART treatment [use of (non)nucleoside 
reverse transcriptase inhibitors, ((N)NRTI), ritonavir boosted protease inhibitor 
(bPI), integrase inhibitors], statin treatment, total cholesterol (TC), high-density 
lipoprotein (HDL-c), LDL-c, TG, CD4 cell count, and HIV-1 RNA. The quantitative 
variables were summarized as median and interquartile ranges (IQR), while 
qualitative variables were presented as frequencies or percentages. 
This article is protected by copyright. All rights reserved. 
The primary endpoint, defined as the proportion of patients not qualifying anymore 
for statin treatment 12 weeks after inclusion into the study (i.e. after 8 weeks of ETR 
treatment) according to EACS 2013 recommendations [11], was analyzed using Mac 
Nemar chi-squared test with a threshold of 5%. We repeated a similar analysis using 
the Swiss cardio-vascular risk score GSLA [16] and 2013 ACC/AHA guideline (10 
year ASCVD risk) [18]. 
 
We analyzed changes in lipid profile and biomarkers as change from baseline to 
week 4 for all the 31 enrolled patients and as change from week 4 to week 12 (8 
weeks) for the 27 patients who switched to ETR. Both absolute and percentage 
changes were assessed and compared using a Wilcoxon matched-pair signed-rank 
test with an alpha threshold of 5%. Correlations between continuous variables were 
evaluated using Spearman’s rank correlation test.  
 
Univariable and multivariable logistic regressions were performed to identify factors 
associated with the impact of ETR switch on statin indication. The univariable 
logistic regression model included age, sex (women vs. men), time since HIV 
diagnosis (>10 years vs. ≤10 years), CD4 cell count (>500 cell/mL vs. ≤500 cell/mL), 
baseline ART class (EFV vs. bPI-based regimen), known hypertension (Yes vs. No), 
smoking status (active smoker vs. non-smoker), LDL-c at week 4 after statin 
interruption, statin half-lives (‘long acting’ (atorvastatin and rosuvastatin) vs. ‘short 
acting’ (pravastatin) [22]) and the 8-weeks percentage change relative to week 4 
(week 4 – week 12) of the four biomarkers MCP-1/CCL2, sICAM, CCL5/RANTES 
and TIMP-1, which changes were statistically significant between the 2 timepoints. 
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The multivariable linear regression model included all variables with a p < 0.200 in 
the univariable model.  
 
The frequency of adverse event of all patients until study completion was recorded 
regardless of the ETR switch. We also analyzed modification of liver and kidney 
function (ASAT [UI], ALAT [UI], serum creatinine [µmol/L]) and glycaemia 
(mmol/L) from week 4 to week 12 for all patients who completed the trial. Eight-
week absolute changes were assessed and compared using a Wilcoxon matched-pair 
signed-rank test with an alpha threshold of 5%. 
 
All statistical analyses were performed using STATA Statistical Software, Release 
12.0 (Stata Corporation, and College Station, USA). The study results were reported 
according to STROBE statement [23]. 
 
Results  
Baseline Characteristics 
From February 2012 to April 2013, 34 patients were screened at the 6 study sites 
within the SHCS (Fig. 1). Three patients were not included, each for one of the 
following reasons: history of known hypercholesterolemia before ART initiation, 
>20% cardiovascular disease risk score according to Swiss guidelines, and statin 
interruption during the screening period. Of the 31 enrolled patients, a majority were 
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men (n = 25, 81%). Median age was 52 years (IQR, 46–60 years) (Table 1). All 
participants had a long history of HIV infection with a median of 11.5 years (IQR, 
7.7-18.9) since diagnosis. At enrolment, the median CD4 cells count was 709 
cells/mL (IQR, 543–851 cells/mL), and all patients had HIV-1-RNA ≤50 copies/mL. 
The ART combination at inclusion included EFV for 21 patients (68%) while 10 
patients (32%) were on a ritonavir-boosted regimen (5 on LPV/r, 4 on ATV/r, 1 on 
DRV/r). Twelve patients (39%) were active smokers, 10 patients (32%) were treated 
for high blood pressure and 2 patients had a family history of cardiovascular disease. 
Statin treatment was pravastatin for 15 patients (48%), rosuvastatin for 13 patients 
(42%) and atorvastatin for 3 patients (10%), with 9 patients (69%) on a daily dose of 
rosuvastatin at 10 mg or higher, 12 patients (80%) on pravastatin at 40 mg or higher, 
and 2 patients (67%) on atorvastatin 20 mg or higher.  
 
Changes in lipid profile 4 weeks after statin withdrawal 
Between week 0 and week 4, median LDL-c increased by 31.0%, median TC 
increased by 21.9%, and median TG by 28.4% (Table 2). These changes were 
statistically significant (p < 0.001), no significant change was observed in HDL-c 
(Figure 2). Two participants had an LDL value < 3 mmol/L and were therefore not 
switched to ETR. Of the remaining patients, 2 were excluded because of HIV-1 RNA 
> 50 copies/mL or the drug resistance mutation M184V. Therefore, of the 31 
included patients, 27 patients switched to the ETR treatment. 
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Statin indication at study completion (8 weeks after switch to ETR)  
At study completion, of the 27 patients who switched to ETR, 25 patients (93%) had 
a viral load below the detection threshold of 50 copies/mL (two patients had a VL 
between 50 and 100 copies/ml). We observed statistically significant decreases in 
total cholesterol (-0.88 mmol/L), LDL-c (-0.49 mmol/L), and TG (-0.51 mmol/L) 
between weeks 4 and 12 (Figure 2).  
 
Primary efficacy endpoint 
At study completion, 15 (56%) of the 27 patients who switched to ETR did not 
qualify for statin treatment according to EACS recommendations (p = 0.0001), and 
14 (52%) patients according to the Swiss GSLA scores (p = 0.0001). A post hoc 
analysis was performed to evaluate the study results using the new American 2013 
ACC/AHA guidelines: only 10 patients (37%) would not qualify anymore for statin 
treatment (p =0.002) (Figure 3). 
 
Cardiovascular biomarkers 
Absolute and percentage changes in inflammatory biomarkers were not significantly 
different between baseline and week 4 after the statin interruption (Table 2). In 
patients who switched to ETR, we observed a decrease in sICAM levels of 11.2% 
(p = 0.039), and a decrease in MCP1/CCL2 levels of 18.9% (p = 0.017) between 
weeks 4 and 12, i.e. during the 8 weeks of ETR administration. In addition, the levels 
of the pro-atherosclerotic chemokine CCL5/RANTES increased by 14.3% (p = 
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0.012), and those of TIMP-1 increased by 13.4% (p = 0.039). Other biomarkers 
showed no significant changes between the different time points, while D-dimers, IL-
6 and TNF-alpha remained below the detection thresholds throughout the study 
period.  
 
Adjusted multivariable analysis 
The only variable found to be related to the absence of indication for statin treatment 
at study completion, after 8 weeks on ETR was age (OR: 1.18 (95% CI, 1.02-1.37)), 
after adjustment for both LDL-c at week 4 (OR: 0.17 (95% CI, 0.02-1.36)) and 
percentage change of TIMP-1 biomarker (OR: 1.02 (95% CI, 1.00-1.01)) (Table 3).  
 
Safety 
No Serious Adverse Event was reported during the study. One patient discontinued 
ETR treatment on his own initiative after 24 days due to dizziness, fatigue and 
depression, which were graded as mild by the investigator. Fifteen clinical events 
were reported in 11 patients. All events were graded as mild or moderate in severity 
and none were judged by the investigator to be related to the study drug, or the statin 
interruption. Nine events were considered possibly related to ETR: one case of grade 
1 rash occurred 2 weeks after ETR initiation, and a case of acute renal failure was 
reported at the end of the study period. Events of dizziness, vomiting, left intercostal 
pain, and a grade 1 elevation of alanine aminotransferase were considered as related 
to the ETR treatment. No significant increase in liver function test was recorded, but 
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a small significant increase in serum creatinine (+4 µmol/L, IQR -2 – 9, p=0.018) 
and a decrease in glycaemia (-0.25 mmol/L, IQR -0.60 – 0.15, p=0.028) were 
observed in the 29 patients who completed the trial, though without clinical impact. 
 
Discussion 
Our study shows that HIV-infected individuals on statin treatment in whom the 
boosted PI or EFV was replaced with ETR can avoid the use of statins in 56% of the 
cases (primary efficacy endpoint). Over the study period, these patients showed a 
significant decrease in the levels of serum lipids (though not as large as when they 
were on statin treatment) and in pro-inflammatory markers, suggesting reduced risk 
of cardiovascular disease.  
 
In addition, we confirmed that statin interruption did not cause any Serious Adverse 
Event as expected from an earlier report [24], and no cardiovascular disease was 
observed during the 12-week study period.  
 
Traditional CV risk factors, HIV-induced immune activation, as well as the 
metabolic consequences of some antiretroviral drugs contribute to a 2-fold increase 
in the risk of cardiovascular disease in HIV-infected patients. Recommended 
preventive interventions target modifiable risk factors such as smoking, and 
dyslipidaemia. Replacing a combined ART component by a lipid-friendly drug has 
many advantages, including economic and practical considerations. However, despite 
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the positive effect on lipids of ETR, a drug such as EFV is available in combination 
as a single fixed-dose pill and is often preferred by patients. Other drugs may have a 
safety and lipid-neutral profile similar to ETR, but have not been evaluated so far 
with the objective of a statin-sparing strategy. 
 
Our results confirm the observations from clinical trials comparing newer drugs with 
standard treatments including boosted PI. In the Switch-EE study [13], patients 
switched to ETR had lower lipid plasma levels than when on EFV. In the SENSE 
study [25] both total cholesterol and LDL-c were lower in patients on ETR as 
compared with patients on EFV (number of patients with grade 3 or 4 elevation of 
total cholesterol was 1% vs. 8%). In the C227 trial [26], exploring two treatment 
regimens (ETR+2NRTI or boosted PI+2NRTI) after an NNRTI-first line failure, 
lipid and bilirubin elevations were less frequent in the ETR arm. These observations 
can be applied in a clinical pragmatic intervention to reduce lipid levels and therefore 
cardiovascular risk.  
 
The so-called “neutral” effect on lipids of ETR has been showed in studies using 
placebo [27] and this may explain its favourable profile compared with antiretroviral 
drugs known for their unwanted effect on lipids. This effect is usually measured at 24 
weeks in clinical trial, but seems to start earlier, as in our study. 
 
Our study focused on numerous cardiovascular risk biomarkers, including active 
factors of atherogenesis previously investigated in both high-risk populations as well 
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as HIV patients [10, 28]. The levels of these mediators in the present study were 
similar to those observed in previous studies [29]. Serum levels of IL-6, TNF-alpha 
and D-dimer were confirmed to be very low in HIV patients as well as in other 
subjects with elevated cardiovascular risk [10, 28]. These results indicate that despite 
their promise in other cohorts [19], these mediators might not be useful in HIV 
patients. Alternatively, our data might also suggest the need for methods providing a 
higher sensitivity for investigating these biomarkers in HIV-positive patients. During 
the four weeks following statin interruption no significant modification in any of 
these biomarkers was seen, in contradiction to previous studies that showed that 
statins lower serum CRP levels [30-31]. The discrepancy could be due to the 
relatively short follow-up; four weeks might not be enough time to observe an 
inflammatory rebound due to statin cessation.  
 
The switch to ETR was associated with a protective decrease in sICAM (a marker of 
endothelial activation) and MCP1/CCL2 (a pro-atherosclerotic chemokine), and a 
beneficial increase in TIMP-1. These changes indicate a potential direct 
cardiovascular protection induced by ETR that may improve endothelial activation, 
protect from the deleterious activities of MMP, and reduce atherosclerotic 
inflammation (via MCP-1/CCL2-mediated pathways). The weak association between 
lipid profile and biomarkers (only shown for TGs and MCP-1/CCL2) suggests that 
ETR might reduce the cardiovascular risk not only via improvement in the lipid 
profile, but also via biomarkers. 
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A study in healthy volunteers [32] showed no effect of ETR on inflammatory 
biomarkers and endothelial function and finally on CV risk. ETR was introduced 
over 28 days with no significant changes, but the study population was very 
different: not only patients had no HIV infection but they had also a normal lipid 
profile, making comparisons difficult. In addition the ETR exposure was only of 28 
days that could be a too short period to observe changes. 
 
We also found a weak but statistically significant increase in the serum levels of the 
chemokine CCL5/RANTES in HIV-infected patients on ETR. This chemokine was 
recently shown to activate both circulating leukocytes and platelets and potentially 
increase cardiovascular vulnerability [28, 33]. Considering the design and low 
number of patients enrolled in our study, we might only speculate that results on this 
marker merit additional investigations. In addition, we cannot conclude whether 
ETR-associated increase of CCL5 levels is limited to the first eight weeks of 
treatment, or sustained over time.  
 
Our study has several limitations. It was not a randomised design, and bias in 
selection of participants cannot be excluded. The lack of a control group prevents the 
clear attribution of the effect of the intervention, but previous studies’ results and the 
appearance of the effect after ETV introduction make the relation plausible. 
Recruitment varied by centre depending on the number of patients already receiving 
statin treatment. Fewer patients were receiving statin treatment than expected, while 
many patients were excluded because of previous cardiovascular disease and/or 
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documented drug mutations. Pill burden and refusal to change regimens were the 
main reasons for non-participation, especially for patients receiving a once daily 
fixed-dose combination such as Atripla®. As a result of insufficient recruitment, the 
desired sample size of 40 included patients was not achieved, thereby reducing the 
power of the study and the possibility to study additional predictive factors. 
 
The criteria for the initial indication of statin treatment were not known and probably 
differed widely across study sites, which adds possible confounding factors not 
considered in our analysis. The study has a short follow-up period, which does not 
allow evaluation of the long-term effect of the proposed treatment strategy, but in a 
previously reported clinical trial, the effect of switch to ETR on lipid profile could be 
maintained over the follow-up period of 48 weeks [34]. We did not collect 
information on nutrition or physical activities, which may have contributed to the 
lipid changes over the study period. 
 
In conclusion, although surrogate experimental biomarkers of CV risk have been 
widely investigated, their clinical use requires further validation in this population. 
Our preliminary results demonstrating the lowering effect of ETR on circulating pro-
inflammatory markers cannot yet be considered as a relevant reduction in CV risk for 
HIV patients. Combination of serum inflammatory biomarkers with other validated 
and classical parameters (i.e. LDL-cholesterol) remain essential when assessing the 
CV risk. Additional larger trials are needed to clarify the role of some biomarkers 
such as CCL2 to further improve the CV risk assessment of HIV-infected patients. 
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While indications for statin use in primary prevention of cardiovascular disease are 
controversial [16-18], the present study indicates that out of the 27 HIV-positive 
patients who switched to ETR for 8 weeks, 10–15 patients (depending on the 
guideline used) or 37–56% no longer required statin treatment. In view of the 
importance of this finding for the management of HIV patients, further 
investigations, including prospective, large-scale, randomised studies with a longer 
follow-up period, are required to justify the switch to ETR and removal of statins 
from the treatment regimen in HIV patients with a low-to-moderate Framingham risk 
score. 
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Table 1. Baseline characteristics of the 31 included patients. 
 Characteristic Value 
Age, years, median (IQR) 51.7 (46.2-59.6) 
Weight, kg, median (IQR) 70 (64-82) 
Gender  
   Men 25 (81%) 
   Women 6 (19%) 
Menopausal women  4 (67%) 
Active Smoker 12 (39%) 
Myocardial infarction or stroke in 1st degree related 
person 2 (7%) 
Known hypertension 10 (32%) 
GSLA Score    
   Low risk < 10% 29 (94%) 
   Moderate risk 10-20% 2 (6%) 
CD4+ cells/mL (IQR) 709 (543-851) 
Time since HIV diagnosis, years (IQR) 11.5 (7.7-18.9) 
HIV staging (CDC categories)   
   A 15 (48%) 
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   B 8 (26%) 
   C 8 (26%) 
On ART treatment 31 (100%) 
First line regimen 3 (10%) 
Current NNRTI 21 (68%) 
Current NRTI 31 (100%) 
Current PI 10 (32%) 
Current INI 1 (3%) 
HIV-RNA ≤ 50 copies/mL 31 (100%) 
Statins in use at study entry:  
   Atorvastatin 3 (10%) 
   Pravastatin 15 (48%) 
   Rosuvastatin 13 (42%) 
IQR = Inter-quartile Range CDC = Centre for Disease Control, USA, NNRTI = non-nucleoside reverse-
transcriptase inhibitor, NRTI = nucleoside reverse-transcriptase inhibitor, PI = protease inhibitor, INI = integrase 
inhibitor. 
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Table 2: Lipid profile and cardiovascular biomarker values 
Patients who stopped statin (N=31) Patients who switched to ETR (N=27) 
  
Week 0 
 
4-week absolute change
 
(Week 0 – Week 4) 
4-week percentage change
 
(Week 0 – Week 4) 
Week 4 
 
8-week absolute change
 
(Week 4 – Week 12) 
8-week percentage change
 
(Week 4 – Week 12) 
  Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Lipids profile             
LDL –C (mmol/l) 2.89 (2.59-3.54) 0.99 (0.54-1.52)*** 31.03 (13.67-65.86)*** 4.30 (3.75-4.75) -0.49 (-1.16; 0.17)* -11.86(-24.17-3.94)*
HDL-C (mmol/l) 1.53 (1.27-1.68) -0.07 (-0.19-0.05) -3.41 (-12.76-3.68) 1.46 (1.25-1.46)  0.01 (-0.17; 0.09) 0.68(-7.33-6.67) 
Total Cholesterol (mmol/l) 5.58 (5.04-6.24) 1.25 (0.78-1.60)*** 21.85 (11.83-31.77)*** 6.97 (6.44-7.36) -0.88 (-1.38; -0.31)*** -13.21(-19.12--3.85)*** 
Triglycerides (mmol/l) 1.63 (1.22-2.62) 0.39 (0-0.62)* 28.36 (0-40.82)** 2.08 (1.37-3.01) -0.51 (-1.16;-0.06)** -27.36(-39.23--4.65)** 
Biomarkers             
Endothelial activation:             
sICAM (ng/mL) 278.56(223.69-336.79) 2.00(-72.12-71.14) 0.46(-21.72;32.77) 272.46(225.6-355.42) -34.45(-67.04-18.74)* -11.21(-22.72;4.58)*
sVCAM (ng/mL) 426(366.56-560.2) -54.87(-123.71-47.31) -13.34(-28.87;5.29) 382.95(289.33-510.44) 8.33(-52.19-78.57) 2.67(-9.07;28.96) 
E-Selectin (ng/mL) 33.66(25.45-44.88) -1.56(-10.14-5.42) -5.41(-25.76;14.53) 33.65(18.82-49.15) -2.85(-7.66-6.43) -7.75(-24.12;22.58) 
sP-selectin (ng/mL) 93.53(66.86-116.05) -2.26(-27.95-13.31) -2.33(-24.45;17.46) 89.07(50.76-105.32) -3.93(-17.53-9.99) -3.8(-19.62;11.99) 
L-Selectin (ng/mL) 
 
1783.36(1174.5-2721.42) 168.45(-345.32--602.46) 8.21(-20.32;38.3) 1953.64(1399.46-2500.62) -121.57(-829.88-657.93) -7.93(-34.91;43.88) 
Pro-atherosclerotic molecules 
cytokines and chemokines:             
CRP (µg/mL) 2.98(0.51-9.25) 0.15(-2.37-1.42) 12.81(-38.99;138.96) 2.60(1.28-7.53) -0.55(-2.75-2.2) -20.05(-46.88;82.22)
IL-6 pg/mL 7.80(7.80-7.80) 0(0-0) 0(0;0) 7.80(7.80-7.80) 0(0-0) 0(0;0) 
TNF alpha (pg/mL) 15.60(15.60-15.60) 0(0-0) 0(0;0) 15.60(15.60-15.60) 0(0-0) 0(0;0) 
MCP1/CCL2 (pg/mL) 102.17(74-188.66) 2.03(-19.72-33.4) 2.5(-16.37;26.52) 114.73(73.8-179.89) -14.24(-34.38--0.98)* -18.92(-32.57;-0.94)* 
MIP-1Beta/CCL4 (pg/mL) 104.27(81.4-135.17) 1.87(-13.2-20.31) 1.87(-15.99;20.86) 102.79(74.84-125.35) -2.74(-11.48-9.79) -3.97(-11.15;15.09) 
CCL5 RANTES (ng/mL) 69.53(33.46-103.89) -3.42(-28.4-8.09) -5.88(-38.91;13.87) 46.88(38.25-72.55) 6.89(-9.92-26.33) 14.27(-14.84;80.72)*
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Adipocytokines:             
Leptin (ng/mL) 3.87(1.83-14.03) -0.19(-1.95-0.61) -10.22(-48.15;28.9) 2.68(1.41-8.27) 0.1(-1.04-1.44) 9.28(-32.38;79.67)
Adiponectin (µg/mL) 6.55(4.5-9.65) 0.03(-0.78-1.76) 0.42(-20.52;30.68) 7.46(4.77-10.23) -0.55(-2.57-0.52) -12.85(-26.77;8.67) 
Metalloproteases and inhibitors:             
MMP-9 (ng/mL) 502.28(358.78-719.29) 6.41(-192.38--74.81) 1.79(-41.51;26.65) 411.18(305.09-723.02) -51.8(-218.3-43.95) -12.88(-38.63;32.57)
MMP-8 (ng/mL) 3.18(1.75-4.7) -0.44(-1.6-0.73) -17.14(-40;34.75) 2.72(1.17-4.26) -0.24(-1.04-0.93) -14.55(-44.22;41.19) 
TIMP-1 (ng/mL) 433.74(354.16-549.09) -11.77(-96.5-89.51) -2.58(-24.54;21.28) 429.51(338.51-523.25) 66.31(-39.23-297)* 13.43(-9.02;100.03)* 
TIMP-2 (ng/mL) 68.53(60.98-85.73) -0.61(-9.47-17.42) -0.82(-9.79;20.31) 73.68(62.27-82.67) -1.41(-12.21-22.17) -1.94(-11.76;27.34) 
TIMP-3 (ng/mL) 2.7(1.99-4.7) -0.13(-1.04-0.81) -1.43(-40.44;44.67) 2.49(1.58-4.22) -0.18(-1.43-0.52) -11.19(-46.92;38.76) 
 
CRP = C-reactive protein, IL = interleukin, MCP = monocyte chemoattractant protein, MIP = macrophage inflammatory protein, MMP = matrix metalloproteinase, RANTES = 
Regulated upon Activation, Normal T-cell Expressed, and Secreted, sICAM = serum soluble intercellular adhesion molecule, sVCAM = soluble vascular cell adhesion molecule, TIMP = 
tissue inhibitor of metalloproteinase, TNF = tumour necrosis factor.  
* p<0.05, ** p<0.01, *** p<0.0001. 
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Table 3: The association between baseline characteristics and the absence of indication 
for statin treatment at study completion. 
Factors 
Univariate OR 
(95% CI) 
P 
Value 
Multivariate 
OR (95% CI) P Value 
Age (in year) 1.13 (1.01-1.27) 0.028 1.18 (1.02-1.37) 0.028 
Sex:  
 
    - Male 1 
   
    - Female 0.91 (0.15-5.58) 0.918 
  
Time since HIV diagnosis: 
    
  - ≤10 years 1 
   
    - >10 years 1.29 (0.26-6.27) 0.756 
  
CD4 count, cells/mm3 
    
    - ≤500 0.91 (0.15-5.58) 
   
    - >500 1 0.918 
  
Statin half-life:  
    
    - Short acting statin 1 
 
    - Long acting statin 0.63 (0.14-2.89) 0.548 
  
Baseline ART treatment:  
 
    - NNRTI (efavirenz) 1 
   
    - Protease inhibitor 0.61 (0.11-3.49) 0.582 
  
Known hypertension 3.10 (0.47-19.67) 0.240 
  
Active smoker 0.48 (0.10-2.23) 0.346 
  
LDL-C value (mmol/L) at week 4 0.32 (0.09-1.17) 0.085 0.17 (0.02-1.36) 0.094 
8-week percentage change of laboratory 
marker TIMP-1  
1.01 (1.00-1.03) 0.079 1.02 (1.00-1.01) 0.092 
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8-week percentage change of laboratory 
marker MCP1-CCL2 
1.01 (0.98-1.04) 0.481 
  
8-week percentage change of laboratory 
marker sICAM 
0.99 (0.95-1.02) 0.451 
  
8-week percentage change of laboratory 
marker  
CCL5_RANTES 
1.00 (0.98-1.01) 0.488 
  
LDL-c = low density lipoprotein cholesterol, MCP = monocyte chemoattractant protein, NNRTI, non-nucleoside 
reverse-transcriptase inhibitor, OR = odds ratio, RANTES = Regulated upon Activation, Normal T-cell 
Expressed, and Secreted, sICAM = serum soluble intercellular adhesion molecule, TIMP = tissue inhibitor of 
metalloproteinase. 
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Figure captions 
 
Figure 1. Study flow chart. The flow chart illustrates recruitment and intervention 
flow of all the patients who were screened at the 6 participating sites.  
Figure 2. Lipid profiles at week 0, week 4 and week 12 in the 27 patients who 
switched to ETR. The serum levels of total cholesterol, low density cholesterol, high 
density cholesterol and triglycerides were measured at baseline (week 0), 4 weeks 
after stopping statin treatment (week 4), and 8 weeks after switch to ETR (week 8) in 
the 27 patients who qualified for the ETR switch out of the 31 included patients. 
Values presented are the median and interquartile ranges. 
Figure 3. Proportion of patients not qualifying for a statin treatment after 8 
weeks of ETR treatment. The criteria for qualifying for statin treatment were 
according to the EACS latest recommendations (blue bar), GSLA (red bar), or 2013 
ACC/AHA recommendations (green bar). 
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Figure 1: Study flow chart. 
      
          
 
 
W-1 34 patients screened
W0 – Statin 
interruption 
31 patients included
W4  
W12 29 patients analysed for safety 
3 patients excluded 
- CV risk > 20% 
- High cholesterol before ART 
- Statin interruption for 3 
months 
27 patients received 
ETR instead of their 
previous EFV (n=21) 
or PI (N=10) 
2 patients continued their 
original ART as LDL-c 
remained < 3 mmol/l 
2 patients excluded at week 4: 
- Resistance (M184V mutation)  
- blip (VL= 125)
27 patients analysed for efficacy
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Figure 2: Lipid profiles at week 0, week 4 and week 12 in the 27 patients who 
switched to ETR. 
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Figure 3: Proportion of patients not qualifying for a statin treatment after 8 
weeks of ETR treatment. 
 
